Similarly, the proliferative response of peripheral blood PD-1+CD8+ T cells (quantified as the fold change in the percentage of Ki-67+ cells seven days post-treatment) proved to be a valuable surrogate biological marker for predicting the response to ICIs in NSCLC patients (59). This evidence concerns the gene CD8A and non-small cell lung carcinoma.